Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.73 |
| ▸ | RAF1 | P04049 | 16/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ERN1 | O75460 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.55 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.55 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12023692 | 0.93 | BRAF (0.64) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL12023661 | 0.91 | BRAF (0.72) | BRAFRAF1MAPK11MAPK14 | |
| SCHEMBL12023679 | 0.88 | BRAF (0.68) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL12023655 | 0.88 | BRAF (0.71) | BRAFRAF1ERN1ABL1FGFR1 | |
| SCHEMBL21152542 | 0.84 | BRAF (1.00) | BRAFRAF1EGFR | |
| SCHEMBL20969811 | 0.84 | BRAF (1.00) | BRAFRAF1EGFR | |
| SCHEMBL12024166 | 0.84 | BRAF (0.66) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL12024052 | 0.83 | BRAF (0.67) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL12023686 | 0.82 | BRAF (0.61) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL14561034 | 0.82 | BRAF (0.61) | BRAFRAF1EGFRMAPK8MAP3K20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2251343-A1 | IMIDAZOTHIAZOLES AS P38-KINASE-INHIBITORS | ARQULE, INC. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK8, MAPK7 | BRAF 179/4885RAF1 198/4885EGFR 3772/4885 |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK7, MAPK8 | BRAF 154/4885RAF1 197/4885EGFR 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.